Tweets
de Boysson et al. Incidence GCA across France. Variation in SIR from 7 to 12.Increasing east-west gradient @rheumnow #ACR22 Abstr#0475 https://t.co/XDSSrJcMu5 https://t.co/nlJjcPB3zo
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
Abs 0373 details SpA-uveitis more severe in pts w/ smoking hx, axial & peripheral involvement, BASDAI >4, +HLA-B27, female sex, ^ CRP, hx of B ocular involvement. #ACR22 @RheumNow https://t.co/Fg0v6NVQcI
Dr. Rachel Tate @uptoTate ( View Tweet )
3 years 8 months ago
Mudano et al. explore reasons for COVID-19 vaccine hesitancy. For primary vaccination safety concerns most common reason at 52%. For booster, lack of recommendation from physician biggest factor at 39%. @rheumnow #ACR22 Abstr#0083 https://t.co/ISdTmOjIWs https://t.co/Qr47Or2a6v
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
Sun et al. 44% improved adherence in people with SLE following a 3.8 minute intervention involving improved communication @rheumnow #ACR22 Abstr#0063 https://t.co/sFU1FzLUfB https://t.co/9AIOijpI0j
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
#abst0199 #acr22 @rheumnow phase II study: Izokibep -highly potent IL-17A inhibitor w/small molecular size designed to overcome limitations of monoclonal Abs: dose-dependent improvement in SF36 & PsAID subdomains, notable improvements in sleep, pain& function. Best in enthesitis https://t.co/VSvhr87PK0
Olga Petryna @DrPetryna ( View Tweet )
3 years 8 months ago
This might be the greatest honor of my career - thanks for including me @ACRheum!!
Serious question and I’m not sure I want to know the answer
Did anyone know the answer?
Would be embarrassing 😂🤣😅😳
#ACR22 #KnowledgeBowl #RheumPix @RheumNow https://t.co/GhjXUgCgye
Mike Putman @EBRheum ( View Tweet )
3 years 8 months ago
Daikeler et al. No change in incidence permanent vision loss in GCA at 17%. Late presentation (after PVL) and missed diagnosis key areas for improvement. @rheumnow #ACR22 Abstr#0476 https://t.co/CYBHm8CCBv https://t.co/jIvouncdxw
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
Don't repeat the ENA test!
Retrospect. study 23,438 ENA testing from 19,603 pts: 10% + (mostly Ro52 Ab), 89% neg. 13.4% had ENA test repeated. 96% stable results w/o change Conclusion: ENA results rarely change or yield new diagnosis of AARD #ACR22 @rheumnow abst#0725
TheDaoIndex @KDAO2011 ( View Tweet )
3 years 8 months ago
What's the best tx strategy for SLE-induced severe thrombocytopenia?
This 10-yr retro study by Dr. Cime-Ake et al. showed that RTX provided longer relapse-free survival (vs. CYC, p=0.040). No difference between IV or oral GCs and AZA or MMF. #ACR22 @RheumNow ABST#368 https://t.co/nzXZMY09jx
sheila @RHEUMarampa ( View Tweet )
3 years 8 months ago
Interim RELIANCE registry data of FMF patients treated with Canakinumab shows efficacy and safety of long-term tx including w/ dose adjustments. Abs 0138 #ACR22 @RheumNow https://t.co/ornfXVIw49 https://t.co/eHTIIEhE37
Dr. Rachel Tate @uptoTate ( View Tweet )
3 years 8 months ago
Khursheed @LatikaGupta_ et al. Gender gap in rheumatology leadership. Improvements over time in ACR and some APLAR countries, but remains hugely imbalanced @rheumnow #ACR22 Abstr#0085 https://t.co/gw4HYaRlIY https://t.co/xueC3cfqyu
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
Should you repeat the dsDNA? SMART-SLE study
>3400 SLE pts, > 37,582 visits. Pts with fluctuating + results or persistently + had higher rates of SLE flares HR 1.56 (95% CI 1.3-1.87, p< 0.001). Inc or Dec dsDNA Ab > 2X from last visit can predict flares @rheumnow #ACR22 abst#0327
TheDaoIndex @KDAO2011 ( View Tweet )
3 years 8 months ago


